ADMA Biologics (ADMA) vs SELLAS Life Sciences Group (SLS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
SELLAS Life Sciences Group (SLS) has outperformed ADMA Biologics (ADMA) over the past year, gaining 495.3% versus a loss of 27.5%. Over five years, ADMA leads with a +821.8% price change compared with +28.1% for SLS. SELLAS Life Sciences Group is the larger company by market cap ($2.28 billion vs $2.27 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ADMA | SLS |
|---|---|---|
| Share price | $10.14 | $11.31 |
| Market cap | $2.27B | $2.28B |
| 1-day change | -0.39% | -0.26% |
| YTD return | -44.41% | +200.00% |
| 1-year return | -27.52% | +495.26% |
| 5-year return | +821.82% | +28.09% |
| P/E ratio (TTM) | 14.49 | — |
| Forward P/E | 10.75 | — |
| EPS (TTM) | $0.70 | $-0.21 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $20.46 | $15.88 |
| 52-week low | $7.21 | $1.39 |
| Distance from 52-week high | -50.44% | -28.78% |
| Analyst consensus | none | none |
| Avg. price target upside | +67.65% | +187.36% |
| Average volume | 2.63M | 6.56M |
| Shares outstanding | 223.98M | 201.95M |
| Employees | 640 | 13 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SLS has outperformed ADMA by 522.8 percentage points over the past year.
About ADMA Biologics
ADMA stock →ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company operates through ADMA BioManufacturing and Plasma Collection Centers segments.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 640 employees
About SELLAS Life Sciences Group
SLS stock →SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
Health Care · Biotechnology: Pharmaceutical Preparations · 13 employees
ADMA vs SLS FAQ
Which is bigger, ADMA Biologics or SELLAS Life Sciences Group?
SELLAS Life Sciences Group (SLS) is larger, with a market capitalization of $2.28B compared with $2.27B for ADMA Biologics (ADMA).
Which stock has performed better over the past year, ADMA or SLS?
SLS returned +495.26% over the past 12 months, compared with -27.52% for ADMA (price return, excluding dividends). Past performance does not predict future results.
Are ADMA Biologics and SELLAS Life Sciences Group in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for ADMA Biologics and Biotechnology: Pharmaceutical Preparations for SELLAS Life Sciences Group.